Endocrine-disrupting chemicals: economic, regulatory, and policy implications
- PMID: 32707119
- PMCID: PMC7437819
- DOI: 10.1016/S2213-8587(20)30128-5
Endocrine-disrupting chemicals: economic, regulatory, and policy implications
Abstract
Endocrine-disrupting chemicals (EDCs) substantially cost society as a result of increases in disease and disability but-unlike other toxicant classes such as carcinogens-have yet to be codified into regulations as a hazard category. This Series paper examines economic, regulatory, and policy approaches to limit human EDC exposures and describes potential improvements. In the EU, general principles for EDCs call for minimisation of human exposure, identification as substances of very high concern, and ban on use in pesticides. In the USA, screening and testing programmes are focused on oestrogenic EDCs exclusively, and regulation is strictly risk-based. Minimisation of human exposure is unlikely without a clear overarching definition for EDCs and relevant pre-marketing test requirements. We call for a multifaceted international programme (eg, modelled on the International Agency for Research in Cancer) to address the effects of EDCs on human health-an approach that would proactively identify hazards for subsequent regulation.
Copyright © 2020 Elsevier Ltd. All rights reserved.
Conflict of interest statement
Declaration of interests
LNV reports grants from National Institutes of Environmental Health Sciences, funding from the Cornell Douglas Foundation and Great Neck Breast Cancer Coalition, and a grant from Paul G Allen Family Foundation; she has received reimbursement for travel, or in-kind donation of travel accommodations, from Food Packaging Forum, World Federation of Scientists, European Association for Veterinary Pharmacology & Toxicology, Stowe Cancer Survivors Group, Society of Toxicology, and Endocrine Society. BAD has a patent Transgenic clawed frog embryos and use thereof as detectors of endocrine disrupters in the environment. A French patent application filed in 2002 (FR0206669), was extended through a Patent Cooperation Treaty application filled in 2003. Applicants: Centre National de la Recherche Scientifique and Muséum National d’Histoire Naturelle. Inventors: B Demeneix and N Turque. The patent has been extended worldwide: France (2007), Japan (2011), USA (2013), Canada (2013), and Europe (2015) with royalties paid to Watchfrog. BAD and RS report reimbursement for travels from the Endocrine Society. LT reports personal fees from Houghton Mifflin Harcourt and Audible. All other authors declare no competing interests.
References
-
- WHO, UN Environment Programme. The state of the science of endocrine disrupting chemicals – 2012. Geneva: United Nations Environment Programme and World Health Organization, 2013. http://www.who.int/iris/bitstream/10665/78101/1/9789241505031_eng.pdf (accessed March 31, 2020).
-
- Kortenkamp A, Martin O, Faust M, et al. State of the art assessment of endocrine disruptors, final report. Brussels: European Commission, 2011.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous
